HGEN “Phase III may not be necessary for approval in ZUMA-19; precedent is CAR-Ts to date have been approved on Phase II data in UK US, EU, Australia Australia”
So $GILD May start using Lenzilumab to add value and safety to Yescarta sooner after the acquisition of HGEN.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.